Dr. Wierda on Combination Regimens With Venetoclax in CLL

William G. Wierda, MD
Published: Friday, Dec 04, 2015



William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

Updated results of a phase Ib study examining the combination of venetoclax plus rituximab demonstrated deep and durable responses with patients with CLL, Wierda explains. Secondly, a phase III study of venetoclax plus obinutuzumab in patients with relapsed/refractory CLL also showed that the combination demonstrated activity in these patients.

Such combination regimens suggest that there is enhanced activity in patients when venetoclax is combined with a CD20 antibody, such as rituximab. However, Wierda cautions on comparing the efficacy of venetoclax as monotherapy and in combination with rituximab, since more data need to be conducted.

<<< View more from the 2015 ASH Annual Meeting



William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses two combination studies with venetoclax for patients with chronic lymphocytic leukemia (CLL) during the 2015 ASH Annual Meeting.

Updated results of a phase Ib study examining the combination of venetoclax plus rituximab demonstrated deep and durable responses with patients with CLL, Wierda explains. Secondly, a phase III study of venetoclax plus obinutuzumab in patients with relapsed/refractory CLL also showed that the combination demonstrated activity in these patients.

Such combination regimens suggest that there is enhanced activity in patients when venetoclax is combined with a CD20 antibody, such as rituximab. However, Wierda cautions on comparing the efficacy of venetoclax as monotherapy and in combination with rituximab, since more data need to be conducted.

<<< View more from the 2015 ASH Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x